Publications Print Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2024 Sep 15 Epub 2024 Sept 15 View PubMed Shah VS, Irvine C, McWilliams RR, Singh P, Soefje SA. Reducing Cancer Drug Cost: 3-Year Analysis of Automated Dose Rounding in Electronic Health Records. JCO Oncol Pract. 2024 Aug 5; OP2300688 Epub 2024 Aug 05 View PubMed Singh KP, Cooper BA, Paul SM, Ruddy K, Singh AB, Chen J, Pituch KA, Grys TE, Singh P, Batalini F, Hammer MJ, Levine JD, Miaskowski C. Gastrointestinal and Neuropsychological Symptoms Are Associated With Distinct Vomiting Profiles in Patients Receiving Chemotherapy. Oncol Nurs Forum. 2024 Jun 14; 51 (4):361-380 View PubMed Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol. 2024 Jun 13; 31 (6):3342-3349 Epub 2024 June 13 View PubMed Toesca DAS, Cheney SM, Singh P, Stanton ML, Wong WW. On Complete Clinical Response of Basal Cell Carcinoma of the Prostate After Definitive Concurrent Chemoradiation. Adv Radiat Oncol. 2024 Apr; 9 (4):101427 Epub 2023 Dec 23 View PubMed Singh P, Ballas L, Sonpavde GP, Chen RC, Bangs R, Bauman BC, Nagar H, Delacroix SE, Lerner SP, Efstathiou JA. Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. Bladder Cancer. 2024; 10 (3):199-213 Epub 2024 Oct 23 View PubMed Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM Jr, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 Dec; 84 (6):536-544 Epub 2023 Aug 16 View PubMed Ng CT, Bonilla HMG, Bryce AH, Singh P, Herrmann J. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. Curr Cardiol Rep. 2023 Aug; 25 (8):889-899 Epub 2023 July 25 View PubMed El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 Jul 20; 41 (21):3712-3723 Epub 2023 May 16 View PubMed Singh KP, Cooper BA, Tofthagen CS, Fryer JD, Singh P, Pituch K, Zhu Q, Gu H, Hammer MJ, Conley YP, Levine JD, Miaskowski C. Higher Levels of Stress and Neuropsychological Symptoms Are Associated With a High Nausea Profile in Patients With Cancer Receiving Chemotherapy. Oncol Nurs Forum. 2023 Jun 15; 50 (4):461-473 View PubMed Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023 May 1; 9 (5):635-645 View PubMed Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbe C, Joshi H, Snyder W, Mehnert JM. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 May; 11 (5) View PubMed Sarkar S, Min K, Ikram W, Tatton RW, Riaz IB, Silva AC, Bryce AH, Moore C, Ho TH, Sonpavde G, Abdul-Muhsin HM, Singh P, Wu T. Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. Cancers (Basel). 2023 Mar 8; 15 (6) Epub 2023 Mar 08 View PubMed Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol. 2023 Feb 1; 9 (2):180-187 View PubMed Ballas L, Singh P, Lerner SP. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. Urol Oncol. 2023 Jan; 41 (1):35-38 Epub 2020 Nov 03 View PubMed Girardi DM, Ghatalia P, Singh P, Iyer G, Sridhar SS, Apolo AB. Systemic therapy in bladder preservation. Urol Oncol. 2023 Jan; 41 (1):39-47 Epub 2020 Nov 19 View PubMed Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct; 7 (5):100573 Epub 2022 Sept 07 View PubMed Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02. View PubMed Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22 View PubMed Riaz IB, Islam M, Khan AM, Naqvi SAA, Siddiqi R, Khakwani KZR, Asghar N, Ikram W, Hussain SA, Singh P, Warner JL, Sonpavde GP, Odedina FT, Kehl KL, Duma N, Bryce AH. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. Am J Med. 2022 Aug; 135 (8):984-992.e6 Epub 2022 Apr 25 View PubMed Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 Jul; 23 (7):899-909 Epub 2022 June 09 View PubMed Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022 Jul; 175:103706. Epub 2022 May 07. View PubMed Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR, Vandvik PO, Joseph RW, Liu H, Wang Z, Herasevich V, Singh P, Hussain SA, Ho TH, Bryce AH, Pagliaro LC, Murad MH, Costello BA. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021 Dec; 80 (6):712-723 Epub 2021 Apr 03 View PubMed Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 2021 Nov; 128 (5):607-614 Epub 2021 May 18 View PubMed Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho T, Singh P, Bryce AH. Evolving Natural History of Metastatic Prostate Cancer. Cureus. 2020 Nov 14; 12 (11):e11484 View PubMed Kekic A, Seetharam M, Singh P, Kunze K, Golafshar M, Azevedo C, Welp S, Bofferding A, Koep T, Ross J, Nelson E, Grilli C, Samadder J. Integrating pharmacogenomics panel testing for supportive care medications in patients with solid tumors. Journal of Clinical Oncology. 2020 May; 38(Suppl 15):e24114-e24114. Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020 Jan; 80 (1):99-108 Epub 2019 Nov 19 View PubMed Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, Mehnert JM. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. 2019 Aug; 121 (5):417-420 Epub 2019 July 29 View PubMed Bin Riaz I, Umar M, Zahid U, Husnain M, Iftikhar A, McBride A, Bilal J, Javed A, Akbar S, Singh P, Ali Z, Sipra QUAR, Gondal FR, Ahman F, Anwer F. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant. 2018 Oct; 53 (10):1242-1254 Epub 2018 Apr 27 View PubMed Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbe C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 Jun 10; 36 (17):1658-1667 Epub 2017 Oct 05 View PubMed Singh P, Black P. Emerging role of checkpoint inhibition in localized bladder cancer. Urol Oncol. 2016 Dec; 34 (12):548-555 Epub 2016 Oct 21 View PubMed Harryman WL, Hinton JP, Rubenstein CP, Singh P, Nagle RB, Parker SJ, Knudsen BS, Cress AE. The Cohesive Metastasis Phenotype in Human Prostate Cancer. Biochim Biophys Acta. 2016 Dec; 1866 (2):221-231 Epub 2016 Sept 24 View PubMed Harryman WL, Pond E, Singh P, Little AS, Eschbacher JM, Nagle RB, Cress AE. Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers. Am J Transl Res. 2016; 8 (2):940-54 Epub 2016 Feb 15 View PubMed Pal SK, Singh P, Vogelzang NJ. PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward. Clin Genitourin Cancer. 2015 Aug; 13 (4):257-60 Epub 2014 July 14 View PubMed Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr; 13 (2):178-84 Epub 2014 Sept 23 View PubMed Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 2015; 11 (15):2137-48 View PubMed Singh P, Agarwal N, Pal SK. Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol. 2015 Jan; 16 (1):316 View PubMed Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP. EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. J Frailty Aging. 2015; 4 (2):107-10 View PubMed Algotar AM, Hsu CH, Singh P, Stratton SP. Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer. J Diabetes. 2013 Dec; 5 (4):465-70 Epub 2013 May 29 View PubMed Singh P, Algotar AM, Bracamonte ER. Prostatic small cell carcinoma: Diagnosis and management. Journal of Cancer Therapy.2013;4:804-10. Singh P, Kaur H, Lerner RG, Patel R, Rafiyath SM, Singh Lamba G. Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Review. J Gastrointest Cancer. 2012 Mar; 43 (1):36-9 View PubMed Lamba G, Rafiyath SM, Kaur H, Khan S, Singh P, Hamilton AM, Ang DC. Malignant glomus tumor of kidney: the first reported case and review of literature. Hum Pathol. 2011 Aug; 42 (8):1200-3 Epub 2011 Feb 18 View PubMed Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010 Nov-Dec; 17 (6):e234-6 View PubMed Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol. 2010 Apr; 33 (4):213-6 View PubMed Singh P, Aronow WS, Mellana WM, Gutwein AH. Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic. Am J Ther. 2010 Jan-Feb; 17 (1):42-5 View PubMed Singh P, Sharma M, Gandhi K, Nelson J, Kaul A. Acute mesenteric vein thrombosis after laparoscopic gastric sleeve surgery for morbid obesity. Surg Obes Relat Dis. 2010 Jan-Feb; 6 (1):107-8 Epub 2009 Aug 19 View PubMed Singh P, Lai HM, Lerner RG, Chugh T, Aronow WS. Guidelines and the use of inferior vena cava filters: a review of an institutional experience. J Thromb Haemost. 2009 Jan; 7 (1):65-71 Epub 2008 Oct 31 View PubMed Pierre-Louis B, Singh P, Frishman WH. Acute inferior wall myocardial infarction and percutaneous coronary intervention of the right coronary during active labor: a clinical report and review of the literature. Cardiol Rev. 2008 Sep-Oct; 16 (5):260-8 View PubMed PST-20267249 Home Publications